Alira Health

Alira Health

Access and reimbursement pathways for digital health solutions and IVD devices

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular attention is paid to software-based in vitro diagnostics (IVDs). With this point of view, a strong connection between DTx and IVDs is observed.

The recent paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” investigates the current regulatory scenarios and reimbursement approaches adopted for DTx and IVDs.

The initial assumption was that countries apply different regulations for the access to the market and adopt different reimbursement systems for both DTx and IVDs. The final aim was to provide a general comparative overview and identify those aspects that should be better addressed to support the adoption and commercialization of DTx and IVDs.

The paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” is co-authored by Andrea Mantovani, Claudia Leopaldi, and Cassandra Maria Nighswander from Alira Health and Rossella Di Bidino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Graduate School of Health Economics and Management (ALTEMS).

Related news

Case Studies May 8, 2024
Mid-Size Medtech Company with a Borderline Product Defines Strategy for EU Launch
Medtech company sought support in developing a regulatory strategy for the EU launch of their product with an aggressive timeline to launch.
Medical Devices MedTech Regulatory
News May 6, 2024
Alira Health’s CDD Advises TVM Capital Healthcare Investment in neurocare Group AG
We are pleased to have been a Commercial Due Diligence advisor for an investment by TVM Capital Healthcare into neurocare group AG. The Munich-based leader in personalized mental health(...)
CDD Digital Therapeutics
Events April 30, 2024
The MedTech Forum 2024
We are thrilled to announce that we will exhibit and speak at The MedTech Forum 2024.
MedTech Regulatory
Articles April 17, 2024
The Challenges for Medtech in a Complex Regulatory Landscape in 2024
Learn more about what manufacturers in the US and Europe should consider when developing their regulatory strategies and prioritizing their target markets from regulatory affairs expert Mercè Guerra.
Medical Devices MedTech Regulatory
News March 27, 2024
Alira Health Joins Forces with APMA to Advance Podiatric Registry
Alira Health joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and(...)
Real-World Evidence (RWE) Registry-based studies Research and Development Wound Healing
Articles March 18, 2024
WHO Model Lists of Essential Medicines: What You Need to Know 
Our Market Access experts share the importance of the EML for pharma companies and four best practices for a successful application, based on our extensive experience in interactions with the WHO.
Market Access
Events February 21, 2024
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
Italy Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.